A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
the IXORA-R Study Group
科研成果: 期刊稿件 › 文章 › 同行评审
111
引用
(Scopus)